メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
藤田医科大学でコンテンツを検索
ホーム
プロファイル
研究部門
研究成果
医学部・呼吸器内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(17)
研究成果
(164)
フィンガープリント
医学部・呼吸器内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
55%
Immune Checkpoint Inhibitor
52%
Lung Cancer
46%
Epidermal Growth Factor Receptor
42%
Progression Free Survival
35%
Overall Survival
32%
Osimertinib
31%
Programmed Death 1 Ligand 1
30%
Monotherapy
24%
Pembrolizumab
20%
Neoplasm
18%
Retrospective Study
17%
Asthma
17%
Paclitaxel
16%
Immunotherapy
15%
Carboplatin
14%
Docetaxel
13%
Eosinophil Cationic Protein
12%
Afatinib
11%
Pemetrexed
11%
Combination Therapy
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Programmed Cell Death
11%
Cohort Study
11%
Clinical Trial
10%
Adverse Event
10%
Homeobox Protein Nkx 2.1
8%
Pranlukast
7%
Nivolumab
7%
Cachexia
7%
Interstitial Lung Disease
7%
Disease
7%
Malignant Neoplasm
7%
Biological Marker
6%
Bone Metastasis
6%
Pneumonia
6%
Transdermal
6%
Bevacizumab
6%
Atezolizumab
6%
Observational Study
6%
Squamous Cell Carcinoma
6%
Tumor Marker
6%
Survival Rate
6%
Lung Disease
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
80%
Immune Checkpoint Inhibitor
40%
Chemoimmunotherapy
37%
Lung Cancer
27%
Programmed Death 1 Ligand 1
25%
Overall Survival
24%
Retrospective Study
24%
Progression Free Survival
23%
Epidermal Growth Factor Receptor
22%
Monotherapy
21%
Pembrolizumab
16%
Osimertinib
15%
Programmed Cell Death
14%
Neoplasm
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Immunotherapy
14%
Combination Therapy
12%
Prognostic Factor
11%
Endobronchial Ultrasonography
11%
Transbronchial Biopsy
11%
Non-Small Cell Lung Cancer
10%
Cohort Analysis
9%
Interstitial Lung Disease
9%
Lung
9%
Pemetrexed
8%
Homeobox Protein Nkx 2.1
8%
Programmed Cell Death
7%
Cachexia
7%
COVID-19
7%
Squamous Cell Carcinoma
7%
Bone Metastasis
6%
Liver Metastasis
6%
Biological Marker
6%
Computer Assisted Tomography
6%
Paclitaxel
6%
Bevacizumab
6%
Carboplatin
6%
Atezolizumab
6%
Artery
6%
Pulmonary Fibrosis
6%
Maintenance Therapy
5%
Hazard Ratio
5%
Programmed Death-Ligand 1
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
58%
Immune Checkpoint Inhibitors
38%
Programmed Death-ligand 1 (PD-L1)
33%
Chemotherapy
33%
Chemoimmunotherapy
29%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
29%
Monotherapy
20%
Overall Survival
19%
Progression-free Survival
17%
Confidence Interval
16%
Pembrolizumab
16%
Epidermal Growth Factor Receptor
16%
Programmed Death-ligand 1 Expression
14%
Tumor Proportion Score
12%
Japan
8%
Osimertinib
8%
EGFR mutation
8%
Pemetrexed
8%
Treatment Outcome
8%
Phase II Trial
8%
Previously Treated
7%
Carboplatin
7%
Thyroid Transcription factor-1 (TTF-1)
7%
Older Patients
7%
Pulmonary Pleomorphic Carcinoma
7%
Multicenter Retrospective Study
7%
Inhalational Steroids
7%
Non-small Cell Lung Cancer Patients
6%
No Significant Difference
6%
Clinical Factors
6%
Transdermal Drugs
6%
Docetaxel
6%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
5%
Combination Therapy
5%
Hazard Ratio
5%
Chemotherapy Alone
5%
Clinical Efficacy
5%
Japanese Population
5%
Pneumonitis
5%